Long Shortz with Race: Major advancements in lung cancer and AML drugs
Race Oncology (ASX:RAC) CEO Dr Daniel Tillett spoke with host Tylah Tully about two new clinical programs for RC220 in lung cancer and AML. He shared insights into the breakthrough behind RC220’s dual anti-cancer and cardio-protective profile, progress toward clinical trials, and the significance of the upcoming Phase 3 AML study.
Dr Tillett also discussed orphan drug designation and key milestones expected in 2026 as Race prepared for increased clinical activity.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Racura Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Racura Oncology a question about this update.